GlassScriptPhysician profile
Brandon Stutz
NPI 1316588734
$30,937.58
in general payments reported to CMS, 2019-2025
33 companies · $6,929 in 2025
The $6,929 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,372 · 2022: $5,700 · 2023: $6,025 · 2024: $7,911 · 2025: $6,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Travel and Lodging: $1,116 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,658.20 |
| Travel and Lodging | $1,115.63 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $5,320.87 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $4,192.52 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $3,555.19 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,366.16 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,797.66 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,763.95 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,750.06 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Lundbeck LLC | $1,736.19 | 2021-2025 | Rexulti, Brintellix |
| Vanda Pharmaceuticals INC. | $1,576.17 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $961.51 | 2021-2022 | |
| Corium, LLC | $791.21 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $722.57 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $699.50 | 2022-2025 | Auvelity |
| Indivior INC. | $676.77 | 2022-2025 | Sublocade, Perseris |
| Tris Pharma INC | $529.56 | 2023-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $440.50 | 2022-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $431.48 | 2021-2024 | Xelstrym |
| Biogen, INC. | $300.57 | 2024-2025 | Zurzuvae |
| Neuronetics, INC. | $293.12 | 2021-2022 | |
| Bausch Health US, LLC | $169.07 | 2023-2025 | Aplenzin |
| Livanova USA, INC. | $123.87 | 2021-2023 | Vns Therapy Symmetry Model 8103 Generator |
| Braeburn INC. | $120.87 | 2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $115.40 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $102.88 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $74.58 | 2021-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $66.45 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $64.49 | 2021-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $50.71 | 2023-2024 | Quviviq |
| Owp Pharmaceuticals, INC. | $43.36 | 2024-2025 | Subvenite |
| Neos Therapeutics, LP | $34.38 | 2025 | Exxua |
| Sumitomo Pharma America, INC. | $25.15 | 2023 | Latuda |
| Noven Pharmaceuticals, INC. | $22.81 | 2022 | |
| Tempus Ai, INC | $18.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Stutz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.